|
|
 |
|
Viewing report
|
|
|
|
Peru Pharmaceuticals and Healthcare Report Q4 2008
Business Monitor International, Nov 2008, Pages: 62
BMI's Peru Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Peru's pharmaceuticals and healthcare industry.
The Peruvian pharmaceutical market is considered one of the less attractive in the Latin American region, according to BMI’s updated Business Environment Rankings for Q408. However, while Peru is found second from the bottom among the 10 regional markets, its poor placing – due largely to the small market size and low per capita spend on drugs – actually masks a number of opportunities in the market. The government is committed to the improvement of generics penetration, as part of wider healthcare system reform, which has already attracted a number of foreign players. Most recently, in August 2008, USbased Vanguard Pharmaceutical signed a contract to sell the generics portfolio of India’s Arbro Pharmaceutical in Latin America, including Peru, and the Caribbean. Vanguard, which has gained access to some 150 preparations, is in the process of setting up operations in Peru, as well as Brazil and Paraguay, in a bid to compete in government tenders and to create a distribution network to penetrate the private sector.
On the domestic front, the existence of companies engaged in the production of low-cost similares (nonbioequivalent copies of patented medicines that do not infringe process patents) is threatened by the tightening of intellectual property (IP) regulations. Given the extensive poverty in the country, the removal of such products from the market has the potential to negative impact access to medicines for much of the population. On the upside, the market for legitimate generics is expanding, supported by government measures, such as generic substitution, and the growing private-label market, which has been carved by the expanding retail chains.
Other health-related industries are also providing opportunities for foreign players. While the Peru’s medical devices market is expected to grow at a pace below that for the pharmaceutical market, increased public health expenditure should boost the importance of tenders. The recently ratified US Peru Free Trade Agreement (FTA) should provide a major boost for US medical device exports to Peru, given that customs duties on most medical device imports will be removed on implementation of the agreement. By 2012, the market is expected to reach a value of PEN858mn (US$317mn), up from around PEN562mn (US$180mn) in 2007, although major medical purchases by the public sector can distort the overall market value in any given year.
In the meantime, Peru will retain its place among Latin America's investment grade elite, underpinned by our long-held view that Peru's sound macroeconomic fundamentals and robust economy, driven largely by domestic demand, make it a highly attractive destination for long-term foreign investors. Although there are some signs of overheating, and a more rapid deterioration of the current account than previously expected, we see the economy growing at 7.0% this year, with risks currently skewed to the upside. While still strong external demand and record high commodity prices are partly responsible for Peru's impressive performance of late, we note that domestic demand remains the key driver, suggesting to us that the economy will remain relatively well insulated from rising global macroeconomic uncertainty.
Product samples
Samples for this product is available. Please Login/Register to download these samples.
Also available
Peru Pharmaceuticals and Healthcare Report Q1 2008
Peru Pharmaceuticals and Healthcare Report Q2 2008
Peru Pharmaceuticals and Healthcare Report Q3 2008
Customers who bought this item also bought
Peru Pharmaceuticals and Healthcare Report Q1 2009
Peru Pharmaceuticals and Healthcare Report Q4 2009
Peru Pharmaceuticals and Healthcare Report Q1 2008
Peru Pharmaceuticals and Healthcare Report Q2 2008
Peru Pharmaceuticals and Healthcare Report Q3 2008
Peru Pharmaceuticals and Healthcare Report Q2 2009
Peru Pharmaceuticals and Healthcare Report Q3 2007
Peru Retail Report Q4 2009
RFID for Healthcare and Pharmaceuticals 2009-2019
RFID for Healthcare and Pharmaceuticals 2008-2018
Nigeria Pharmaceuticals and Healthcare Report Q2 2008
Nigeria Pharmaceuticals and Healthcare Report Q3 2008
|
|
|
|
